{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T13:18:57Z","timestamp":1789219137642,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The Basic Research Project of the Science and Technology Department of Yunnan Province","award":["NO.202201AT070244"],"award-info":[{"award-number":["NO.202201AT070244"]}]},{"name":"The Basic Research Program of the Science and Technology Department of Yunnan Province","award":["NO.202401AY070001-226"],"award-info":[{"award-number":["NO.202401AY070001-226"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"DOI":"10.1186\/s12959-024-00669-6","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T14:45:03Z","timestamp":1731077103000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The well-defined antiphospholipid syndrome induced by COVID-19: a rare case report and review of the literature"],"prefix":"10.1186","volume":"22","author":[{"given":"Zong-fang","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ri-cheng","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-ling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-huang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-feng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,8]]},"reference":[{"issue":"21","key":"669_CR1","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1056\/NEJMra1705454","volume":"378","author":"D Garcia","year":"2018","unstructured":"Garcia D, Erkan D. Diagnosis and Management of the Antiphospholipid Syndrome. N Engl J Med. 2018;378(21):2010\u201321.","journal-title":"N Engl J Med"},{"key":"669_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-069717","volume":"380","author":"JS Knight","year":"2023","unstructured":"Knight JS, Branch DW, Ortel TL. Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management. BMJ. 2023;380: e069717.","journal-title":"BMJ"},{"issue":"7","key":"669_CR3","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1007\/s10067-020-05180-7","volume":"39","author":"C Gazzaruso","year":"2020","unstructured":"Gazzaruso C, et al. High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia. Clin Rheumatol. 2020;39(7):2095\u20137.","journal-title":"Clin Rheumatol"},{"issue":"2","key":"669_CR4","doi-asserted-by":"publisher","first-page":"e001580","DOI":"10.1136\/rmdopen-2021-001580","volume":"7","author":"M Taha","year":"2021","unstructured":"Taha M, Samavati L. Antiphospholipid antibodies in COVID-19: a meta-analysis and systematic review. RMD Open. 2021;7(2):e001580.","journal-title":"RMD Open"},{"issue":"1","key":"669_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1080\/14397595.2021.1892257","volume":"32","author":"S Karahan","year":"2022","unstructured":"Karahan S, et al. Antiphospholipid antibodies in COVID-19-associated pneumonia patients in intensive care unit. Mod Rheumatol. 2022;32(1):163\u20138.","journal-title":"Mod Rheumatol"},{"key":"669_CR6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.thromres.2020.05.017","volume":"192","author":"F Galeano-Valle","year":"2020","unstructured":"Galeano-Valle F, et al. Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism. Thromb Res. 2020;192:113\u20135.","journal-title":"Thromb Res"},{"issue":"4","key":"669_CR7","first-page":"754","volume":"38","author":"M Gatto","year":"2020","unstructured":"Gatto M, et al. Frequency and clinical correlates of antiphospholipid antibodies arising in patients with SARS-CoV-2 infection: findings from a multicentre study on 122 cases. Clin Exp Rheumatol. 2020;38(4):754\u20139.","journal-title":"Clin Exp Rheumatol"},{"key":"669_CR8","doi-asserted-by":"crossref","unstructured":"Gutierrez Lopez de Ocariz, X., et al., Thrombosis and antiphospholipid antibodies in patients with SARS-COV-2 infection (COVID-19). Int J Lab Hematol, 2020. 42(6): e280-e282.","DOI":"10.1111\/ijlh.13320"},{"key":"669_CR9","doi-asserted-by":"publisher","first-page":"1227547","DOI":"10.3389\/fimmu.2023.1227547","volume":"14","author":"S Oba","year":"2023","unstructured":"Oba S, et al. Thrombosis and antiphospholipid antibodies in Japanese COVID-19: based on propensity score matching. Front Immunol. 2023;14:1227547.","journal-title":"Front Immunol"},{"issue":"7","key":"669_CR10","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1182\/blood-2003-01-0180","volume":"102","author":"P Lieby","year":"2003","unstructured":"Lieby P, et al. Memory B cells producing somatically mutated antiphospholipid antibodies are present in healthy individuals. Blood. 2003;102(7):2459\u201365.","journal-title":"Blood"},{"issue":"1","key":"669_CR11","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/00042737-200012010-00013","volume":"12","author":"GN Dalekos","year":"2000","unstructured":"Dalekos GN, et al. Increased incidence of anti-cardiolipin antibodies in patients with hepatitis C is not associated with aetiopathogenetic link to anti-phospholipid syndrome. Eur J Gastroenterol Hepatol. 2000;12(1):67\u201374.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"669_CR12","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1016\/j.jinf.2006.03.031","volume":"54","author":"V Delbos","year":"2007","unstructured":"Delbos V, et al. Acute cytomegalovirus infection and venous thrombosis: role of antiphospholipid antibodies. J Infect. 2007;54(1):e47-50.","journal-title":"J Infect"},{"issue":"11","key":"669_CR13","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1007\/s10067-007-0581-6","volume":"26","author":"L Galr\u00e3o","year":"2007","unstructured":"Galr\u00e3o L, et al. Antiphospholipid antibodies in HIV-positive patients. Clin Rheumatol. 2007;26(11):1825\u201330.","journal-title":"Clin Rheumatol"},{"issue":"17","key":"669_CR14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2007575","volume":"382","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med. 2020;382(17): e38.","journal-title":"N Engl J Med"},{"key":"669_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.911979","volume":"13","author":"G Espinosa","year":"2022","unstructured":"Espinosa G, et al. Persistent Antiphospholipid Antibodies Are Not Associated With Worse Clinical Outcomes in a Prospective Cohort of Hospitalised Patients With SARS-CoV-2 Infection. Front Immunol. 2022;13: 911979.","journal-title":"Front Immunol"},{"key":"669_CR16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.thromres.2020.07.016","volume":"195","author":"V Siguret","year":"2020","unstructured":"Siguret V, et al. Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients? Thromb Res. 2020;195:74\u20136.","journal-title":"Thromb Res"},{"issue":"15","key":"669_CR17","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.1039\/D3NA00335C","volume":"5","author":"H Kominami","year":"2023","unstructured":"Kominami H, et al. Protein nanoarrays using the annexin A5 two-dimensional crystal on supported lipid bilayers. Nanoscale Adv. 2023;5(15):3862\u201370.","journal-title":"Nanoscale Adv"},{"issue":"2","key":"669_CR18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1006\/jaut.2000.0410","volume":"15","author":"JH Rand","year":"2000","unstructured":"Rand JH. Antiphospholipid antibody-mediated disruption of the annexin-V antithrombotic shield: a thrombogenic mechanism for the antiphospholipid syndrome. J Autoimmun. 2000;15(2):107\u201311.","journal-title":"J Autoimmun"},{"issue":"Supplement 1","key":"669_CR19","doi-asserted-by":"publisher","first-page":"3790","DOI":"10.1182\/blood-2018-99-113486","volume":"132","author":"C Bai","year":"2018","unstructured":"Bai C, et al. Platelet-Derived Microvesicles Reverse the Lupus Anticoagulant Effect and Are More Potent then Synthetic Phospholipids in Supporting Thrombin Generation in Antiphospholipid Syndrome. Blood. 2018;132(Supplement 1):3790\u20133790.","journal-title":"Blood"},{"issue":"4","key":"669_CR20","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1177\/0961203310361485","volume":"19","author":"JH Rand","year":"2010","unstructured":"Rand JH, et al. The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. Lupus. 2010;19(4):460\u20139.","journal-title":"Lupus"},{"issue":"2","key":"669_CR21","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s10495-005-0817-3","volume":"10","author":"K Balasubramanian","year":"2005","unstructured":"Balasubramanian K, Maiti SN, Schroit AJ. Recruitment of beta-2-glycoprotein 1 to cell surfaces in extrinsic and intrinsic apoptosis. Apoptosis. 2005;10(2):439\u201346.","journal-title":"Apoptosis"},{"issue":"10","key":"669_CR22","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1182\/blood-2011-02-339564","volume":"118","author":"K Gropp","year":"2011","unstructured":"Gropp K, et al. beta(2)-glycoprotein I, the major target in antiphospholipid syndrome, is a special human complement regulator. Blood. 2011;118(10):2774\u201383.","journal-title":"Blood"},{"issue":"3","key":"669_CR23","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1182\/blood-2009-03-206367","volume":"115","author":"MP Sikara","year":"2010","unstructured":"Sikara MP, et al. beta2 Glycoprotein I (beta2GPI) binds platelet factor 4 (PF4): implications for the pathogenesis of antiphospholipid syndrome. Blood. 2010;115(3):713\u201323.","journal-title":"Blood"},{"key":"669_CR24","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1182\/asheducation-2015.1.53","volume":"2015","author":"S Chaturvedi","year":"2015","unstructured":"Chaturvedi S, McCrae KR. The antiphospholipid syndrome: still an enigma. Hematology Am Soc Hematol Educ Program. 2015;2015:53\u201360.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"19","key":"669_CR25","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1182\/blood-2017-11-814681","volume":"131","author":"A Sacharidou","year":"2018","unstructured":"Sacharidou A, et al. Antiphospholipid antibodies induce thrombosis by PP2A activation via apoER2-Dab2-SHC1 complex formation in endothelium. Blood. 2018;131(19):2097\u2013110.","journal-title":"Blood"},{"issue":"18","key":"669_CR26","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1182\/blood-2014-08-593624","volume":"125","author":"K Tanimura","year":"2015","unstructured":"Tanimura K, et al. beta2-Glycoprotein I\/HLA class II complexes are novel autoantigens in antiphospholipid syndrome. Blood. 2015;125(18):2835\u201344.","journal-title":"Blood"},{"issue":"13","key":"669_CR27","doi-asserted-by":"publisher","first-page":"4312","DOI":"10.1182\/blood-2007-07-100008","volume":"110","author":"Y Yamaguchi","year":"2007","unstructured":"Yamaguchi Y, et al. Excessive exposure to anionic surfaces maintains autoantibody response to beta(2)-glycoprotein I in patients with antiphospholipid syndrome. Blood. 2007;110(13):4312\u20138.","journal-title":"Blood"},{"issue":"14","key":"669_CR28","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1182\/blood-2008-11-188698","volume":"114","author":"Z Romay-Penabad","year":"2009","unstructured":"Romay-Penabad Z, et al. Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo. Blood. 2009;114(14):3074\u201383.","journal-title":"Blood"},{"issue":"10","key":"669_CR29","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1177\/0961203308095329","volume":"17","author":"E Cockrell","year":"2008","unstructured":"Cockrell E, Espinola RG, McCrae KR. Annexin A2: biology and relevance to the antiphospholipid syndrome. Lupus. 2008;17(10):943\u201351.","journal-title":"Lupus"},{"issue":"13","key":"669_CR30","doi-asserted-by":"publisher","first-page":"6836","DOI":"10.3390\/ijms22136836","volume":"22","author":"HI Lim","year":"2021","unstructured":"Lim HI, Hajjar KA. Annexin A2 in Fibrinolysis, Inflammation and Fibrosis. Int J Mol Sci. 2021;22(13):6836.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"669_CR31","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.1182\/blood-2005-07-2636","volume":"107","author":"G Cesarman-Maus","year":"2006","unstructured":"Cesarman-Maus G, et al. Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome. Blood. 2006;107(11):4375\u201382.","journal-title":"Blood"},{"issue":"10","key":"669_CR32","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1177\/0961203308092805","volume":"17","author":"PP Chen","year":"2008","unstructured":"Chen PP, et al. Some antiphospholipid antibodies bind to hemostasis and fibrinolysis proteases and promote thrombosis. Lupus. 2008;17(10):916\u201321.","journal-title":"Lupus"},{"issue":"11","key":"669_CR33","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1111\/jth.13807","volume":"15","author":"EM Gleeson","year":"2017","unstructured":"Gleeson EM, et al. A novel protein C-factor VII chimera provides new insights into the structural requirements for cytoprotective protease-activated receptor 1 signaling. J Thromb Haemost. 2017;15(11):2198\u2013207.","journal-title":"J Thromb Haemost"},{"issue":"3","key":"669_CR34","doi-asserted-by":"publisher","first-page":"741","DOI":"10.3390\/jcm13030741","volume":"13","author":"I Tohidi-Esfahani","year":"2024","unstructured":"Tohidi-Esfahani I, et al. Platelets and Thrombotic Antiphospholipid Syndrome. J Clin Med. 2024;13(3):741.","journal-title":"J Clin Med"},{"issue":"4","key":"669_CR35","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1182\/blood-2014-02-554980","volume":"124","author":"V Proulle","year":"2014","unstructured":"Proulle V, et al. Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS. Blood. 2014;124(4):611\u201322.","journal-title":"Blood"},{"issue":"2","key":"669_CR36","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1136\/annrheumdis-2018-213846","volume":"78","author":"I Uthman","year":"2019","unstructured":"Uthman I, et al. Management of antiphospholipid syndrome. Ann Rheum Dis. 2019;78(2):155\u201361.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"669_CR37","first-page":"CD012169","volume":"10","author":"MM Bala","year":"2020","unstructured":"Bala MM, et al. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. Cochrane Database Syst Rev. 2020;10(10):CD012169.","journal-title":"Cochrane Database Syst Rev"},{"key":"669_CR38","doi-asserted-by":"crossref","unstructured":"Ghembaza, A. and D. Saadoun, Management of Antiphospholipid Syndrome. Biomedicines, 2020. 8(11).","DOI":"10.3390\/biomedicines8110508"},{"key":"669_CR39","doi-asserted-by":"publisher","first-page":"1759720X2091085","DOI":"10.1177\/1759720X20910855","volume":"12","author":"M Rodziewicz","year":"2020","unstructured":"Rodziewicz M, D\u2019Cruz DP. An update on the management of antiphospholipid syndrome. Ther Adv Musculoskelet Dis. 2020;12:1759720X20910855.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"9","key":"669_CR40","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1136\/ard.2011.150268","volume":"70","author":"JA Vargas-Hitos","year":"2011","unstructured":"Vargas-Hitos JA, et al. Efficacy and safety of long-term low molecular weight heparin in patients with antiphospholipid syndrome. Ann Rheum Dis. 2011;70(9):1652\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"669_CR41","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1093\/rheumatology\/41.8.924","volume":"41","author":"D Erkan","year":"2002","unstructured":"Erkan D, et al. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford). 2002;41(8):924\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"669_CR42","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/art.24232","volume":"61","author":"MG Tektonidou","year":"2009","unstructured":"Tektonidou MG, et al. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum. 2009;61(1):29\u201336.","journal-title":"Arthritis Rheum"},{"key":"669_CR43","doi-asserted-by":"crossref","unstructured":"M\u00fcller-Calleja, N., Manukyan, D, Ruf, W, et al. BLOOD. 2016; 128 (22): 5023\u20135023. , Mechanism of Action of Hydroxychloroquine in the Antiphospholipid Syndrome. BLOOD, 2016. 128(22).","DOI":"10.1182\/blood.V128.22.5023.5023"},{"key":"669_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7573\/dic.2020-4-5","volume":"9","author":"AM Shukla","year":"2020","unstructured":"Shukla AM, et al. Chloroquine and hydroxychloroquine in the context of COVID-19. Drugs in Context. 2020;9:1\u20138.","journal-title":"Drugs in Context"},{"issue":"4","key":"669_CR45","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1136\/ard.2010.135525","volume":"70","author":"C Lopez-Pedrera","year":"2011","unstructured":"Lopez-Pedrera C, et al. Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome. Ann Rheum Dis. 2011;70(4):675\u201382.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"669_CR46","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1002\/1529-0131(200112)44:12<2870::AID-ART475>3.0.CO;2-Y","volume":"44","author":"PL Meroni","year":"2001","unstructured":"Meroni PL, et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum. 2001;44(12):2870\u20138.","journal-title":"Arthritis Rheum"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-024-00669-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12959-024-00669-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-024-00669-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T16:02:24Z","timestamp":1731081744000},"score":1,"resource":{"primary":{"URL":"https:\/\/thrombosisjournal.biomedcentral.com\/articles\/10.1186\/s12959-024-00669-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["669"],"URL":"https:\/\/doi.org\/10.1186\/s12959-024-00669-6","relation":{},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,8]]},"assertion":[{"value":"15 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The publication of this case has been authorized by the Scientific Research Ethics Committee of the General Hospital of the Southern Theatre Command of the Chinese People\u2019s Liberation Army (approval number: NZLLKZ2024069).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"99"}}